Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GATE1: Pirtobrutinib, Rituximab and Venetoclax in Untreated Mantle Cell Lymphoma
NCT06522386Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2025
- Primary completion
- Feb 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pirtobrutinib in mantle cell lymphoma (MCL), sponsored by University of Texas MD Anderson Cancer Center. Started Jan 2025; status: active, not recruiting.
02
Drugs
pirtobrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT06522386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06522386.